SCHEMBL4143396

SCHEMBL4143396

CCSC(C(=O)O)c1ccc(NC2=NC(=O)/C(=C\c3cc4ccccc4cc3OC(C)C)S2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.34
ALDH1A1 P00352 4/20 0.33
TDP1 Q9NUW8 3/20 0.33
HPGD P15428 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KMT2A Q03164 5/20 0.33
MEN1 O00255 4/20 0.33
KDM4E B2RXH2 2/20 0.33
RECQL P46063 2/20 0.33
HTT P42858 2/20 0.33
TP53 P04637 1/20 0.33
NPC1 O15118 1/20 0.33
LMNA P02545 1/20 0.33
RAB9A P51151 1/20 0.33
P2RX3 P56373 3/20 0.32
ALOX5 P09917 2/20 0.32
IRAK4 Q9NWZ3 1/20 0.31
PPARG P37231 1/20 0.31
PTP4A3 O75365 2/20 0.31
POLB P06746 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4143401 1.00 MAPT (0.34) MAPTALDH1A1TDP1HPGDSMN1; SMN2
SCHEMBL4137480 0.85 MAPT (0.34) MAPTALDH1A1TDP1HPGDSMN1; SMN2
SCHEMBL4137478 0.85 MAPT (0.34) MAPTALDH1A1TDP1HPGDSMN1; SMN2
SCHEMBL4128924 0.83 S1PR1 (0.43) MAPTALDH1A1TDP1HPGDSMN1; SMN2
SCHEMBL4128926 0.83 S1PR1 (0.43) MAPTALDH1A1TDP1HPGDSMN1; SMN2
SCHEMBL4121679 0.78 PDE5A (0.37) MAPTALDH1A1TDP1HPGDSMN1; SMN2
SCHEMBL4121677 0.78 PDE5A (0.37) MAPTALDH1A1TDP1HPGDSMN1; SMN2
SCHEMBL4122595 0.76 PTP4A3 (0.46) MAPTALDH1A1TDP1SMN1; SMN2KMT2A
SCHEMBL4122600 0.76 PTP4A3 (0.46) MAPTALDH1A1TDP1SMN1; SMN2KMT2A
Acetic Acid SCHEMBL4635217 0.74 CHEK1 (0.39) MAPTALDH1A1TDP1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP disclosed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ MAPT 3532/4885ALDH1A1 216/4885TDP1 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.